Drug Profile
MK 6325
Alternative Names: MK-6325Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Germany (PO, Capsule)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in Moldova (PO, Capsule)
- 30 Apr 2012 Merck completes a phase I trial in Hepatitis C in Germany & Moldova (NCT01329913)